A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

BACKGROUND: Mutations in the tumor-suppressor gene VHL cause oversecretion of vascular endothelial growth factor by clear-cell renal carcinomas. We conducted a clinical trial to evaluate bevacizumab, a neutralizing antibody against vascular endothelial growth factor, in patients with metastatic rena...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Yang, James C., Haworth, Leah, Sherry, Richard M., Hwu, Patrick, Schwartzentruber, Douglas J., Topalian, Suzanne L., Steinberg, Seth M., Chen, Helen X., Rosenberg, Steven A.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2003
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2275324/
https://ncbi.nlm.nih.gov/pubmed/12890841
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa021491
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items